Kestra Advisory Services, LLC Seagen Inc. Transaction History

Kestra Advisory Services, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$127.59 - $203.08 $857,659 - $1.37 Million	-6,722 Reduced 70.32%	2,837 $574,000
Q4 2022 Jan 31, 2023	BUY	$117.37 - $139.17 $452,578 - $536,639	3,856 Added 67.61%	9,559 $1.23 Million
Q3 2022 Nov 01, 2022	BUY	$135.27 - $180.11 $305,169 - $406,328	2,256 Added 65.45%	5,703 $780 Million
Q2 2022 Aug 12, 2022	SELL	$108.81 - $179.33 $98,581 - $162,472	-906 Reduced 20.81%	3,447 $610,000
Q1 2022 Apr 26, 2022	BUY	$119.61 - $157.85 $285,389 - $376,630	2,386 Added 121.3%	4,353 $627,000

Q4 2021 Jan 20, 2022	SELL	$142.57 - $190.86 $164,383 - $220,061	-1,153 Reduced 36.96%	1,967 $304,000
Q3 2021 Oct 19, 2021	SELL	$142.45 - $169.82 $82,193 - $97,986	-577 Reduced 15.61%	3,120 $529,000
Q2 2021 Jul 28, 2021	BUY	$135.08 - $161.1 $3,377 - $4,027	25 Added 0.68%	3,697 $583,000
Q1 2021 May 10, 2021	BUY	$137.51 - $190.8 $319,023 - $442,656	2,320 Added 171.6%	3,672 $509,000
Q4 2020 Jan 20, 2021	BUY	$164.63 - $211.93 $222,579 - $286,529	1,352 New	1,352 $248 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Kestra Advisory Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Kestra Advisory Services, LLC with notifications on news.